Search Result

Results for "

TYK2 JH2 domain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug Derivative (1) IFNAR (6) Interleukin Related (6) Isotope-Labeled Compounds (2) JAK (13) STAT (3)
By Research Areas:	Cancer (5) Inflammation/Immunology (10)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: Discoidin Domain Receptor Epigenetic Reader Domain EHD Protein WDR5 YTHDF PASK/STK37 VISTA SHP1 PIKfyve BCL6 PNPLA3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117287

Deucravacitinib 30+ Cited Publications BMS-986165	JAK STAT Interleukin Related IFNAR	Inflammation/Immunology
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of *TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3* and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

HY-150096

Zasocitinib 1 Publications Verification NDI-034858; TAK-279	JAK	Inflammation/Immunology
Zasocitinib (NDI-034858) is a *TYK2* inhibitor, target **TYK2 JH2** domain with binding constant K_d of <200 pM .

HY-153701S

Envudeucitinibum Envudeucitinib; ESK-001	JAK Interleukin Related IFNAR Isotope-Labeled Compounds	Inflammation/Immunology
Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active *TYK2* inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

HY-126242S

Tyk2-IN-7	JAK IFNAR Interleukin Related	Inflammation/Immunology
Tyk2-IN-7 is an orally active *TYK2* JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits *TYK2/JAK1/JAK2* kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-111745

Tyk2-IN-5	JAK	Inflammation/Immunology
Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the *JH2* structural domain. Tyk2-IN-5 shows a K_i value of 0.086 nM for **Tyk2 JH2 and an IC₅₀** value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .

HY-156466

QL-1200186	STAT Interleukin Related IFNAR	Inflammation/Immunology
QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase *TYK2* pseudokinase domain *JH2* (IC₅₀=0.06 nM, **TYK2 JH2*), with 164-fold selectivity over TYK1 JH2* (IC₅₀=9.85 nM，TYK1 *JH2). QL-1200186 first stabilizes the TYK2* JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .

HY-E70873

Tyk2(JH1/JH2) Recombinant Human Active Protein Kinase	JAK	Cancer
TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). Tyk2(JH1/JH2) Recombinant Human Active Protein Kinase is a recombinant Tyk2(JH1/JH2) protein that can be used to study Tyk2(JH1/JH2)-related functions .

HY-E70874

TYK2(JH2) Recombinant Human Active Protein Kinase	JAK	Cancer
TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). TYK2(JH2) Recombinant Human Active Protein Kinase is a recombinant TYK2(JH2) protein that can be used to study TYK2(JH2)-related functions .

HY-149892S

TYK2 JH2-IN-1-d3	JAK	Cancer
TYK2?JH2-IN-1-d₃ is the a deuterated, orally active and selective TYK2 inhibitor (compound 4h), targeting to JH2 domain (IC₅₀=0.1 nM) .

HY-117287A

Deucravacitinib (hydrochloride) BMS-986165 (hydrochloride)	IFNAR STAT Interleukin Related JAK	Inflammation/Immunology
Deucravacitinib (BMS-986165) hydrochloride is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of *TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib hydrochloride blocks IL-23, IL-12, p-STAT1/3* and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib hydrochloride can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

HY-163312S

Tyk2-IN-18-d5	JAK	Inflammation/Immunology
Tyk2-IN-18-d5 (Compound 13) is the deuterated *TYK2* inhibitor, targeting to JH2 domain. Tyk2-IN-18-d5 can be used for the research of inflammatory and autoimmune diseases .

HY-181278

Deucravacitinib analog 1	Drug Derivative JAK	Inflammation/Immunology Cancer
Deucravacitinib analog 1 (compound 3), Deucravacitinib (HY-117287) derivative, is a *TYK2* allosteric ligand. Deucravacitinib analog 1 binds to the JH2 domain of TYK2. Deucravacitinib analog 1 serves as a starting point for development of TYK2-targeting PROTAC degraders. Deucravacitinib analog 1 can be used for the researches of psoriasis and cancer .

HY-E70872

TYK2(JH1) Recombinant Human Active Protein Kinase	JAK	Cancer
TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). TYK2(JH1) Recombinant Human Active Protein Kinase is a recombinant TYK2(JH1) protein that can be used to study TYK2(JH1)-related functions .

HY-166594S

Deucravacitinib-13C,d3	Isotope-Labeled Compounds IFNAR Interleukin Related JAK	Inflammation/Immunology
Deucravacitinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric *TYK2* inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .

Cat. No.	Product Name	Chemical Structure

HY-117287

Deucravacitinib 30+ Cited Publications
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of *TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3* and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

Deucravacitinib

30+ Cited Publications

Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

HY-153701S

Envudeucitinibum
Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active *TYK2* inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

Envudeucitinibum

Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

HY-126242S

Tyk2-IN-7
Tyk2-IN-7 is an orally active *TYK2* JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits *TYK2/JAK1/JAK2* kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

Tyk2-IN-7

Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-149892S

TYK2 JH2-IN-1-d3
TYK2?JH2-IN-1-d₃ is the a deuterated, orally active and selective TYK2 inhibitor (compound 4h), targeting to JH2 domain (IC₅₀=0.1 nM) .

HY-163312S

Tyk2-IN-18-d5
Tyk2-IN-18-d5 (Compound 13) is the deuterated *TYK2* inhibitor, targeting to JH2 domain. Tyk2-IN-18-d5 can be used for the research of inflammatory and autoimmune diseases .

HY-166594S

Deucravacitinib-13C,d3
Deucravacitinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric *TYK2* inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .

Deucravacitinib-13C,d3

Deucravacitinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.